Brokerages Set KORU Medical Systems, Inc. (NASDAQ:KRMD) Price Target at $6.13

KORU Medical Systems, Inc. (NASDAQ:KRMD) has been given a consensus recommendation of “Moderate Buy” by the six brokerages that are presently covering the firm, MarketBeat Ratings reports. One research analyst has rated the stock with a sell recommendation, one has given a hold recommendation, three have assigned a buy recommendation and one has given a strong buy recommendation to the company. The average 1-year target price among brokers that have issued ratings on the stock in the last year is $6.1250.

KRMD has been the subject of several research analyst reports. Wall Street Zen upgraded shares of KORU Medical Systems from a “buy” rating to a “strong-buy” rating in a research note on Monday, January 12th. Lake Street Capital boosted their price target on KORU Medical Systems from $6.00 to $8.00 and gave the company a “buy” rating in a research note on Monday, December 22nd. Weiss Ratings reiterated a “sell (d-)” rating on shares of KORU Medical Systems in a research report on Thursday, January 22nd. Canaccord Genuity Group lifted their price objective on KORU Medical Systems from $5.00 to $6.00 and gave the stock a “buy” rating in a report on Wednesday, December 17th. Finally, Craig Hallum restated a “buy” rating and issued a $7.00 target price on shares of KORU Medical Systems in a research note on Tuesday, January 13th.

KORU Medical Systems Stock Up 1.7%

KORU Medical Systems stock opened at $4.85 on Monday. KORU Medical Systems has a twelve month low of $1.86 and a twelve month high of $6.61. The company has a debt-to-equity ratio of 0.01, a quick ratio of 1.92 and a current ratio of 2.48. The firm has a market cap of $224.65 million, a PE ratio of -60.63 and a beta of 0.47. The firm’s 50 day moving average price is $5.31 and its two-hundred day moving average price is $4.78.

Institutional Investors Weigh In On KORU Medical Systems

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Police & Firemen s Retirement System of New Jersey acquired a new stake in KORU Medical Systems in the 2nd quarter valued at about $30,000. BNP Paribas Financial Markets lifted its position in shares of KORU Medical Systems by 52.1% in the third quarter. BNP Paribas Financial Markets now owns 10,148 shares of the company’s stock valued at $39,000 after buying an additional 3,478 shares during the last quarter. Lazard Asset Management LLC acquired a new stake in shares of KORU Medical Systems in the second quarter valued at approximately $59,000. Acadian Asset Management LLC bought a new position in shares of KORU Medical Systems during the 1st quarter worth approximately $63,000. Finally, Intech Investment Management LLC acquired a new position in shares of KORU Medical Systems during the 2nd quarter worth approximately $73,000. Institutional investors own 58.60% of the company’s stock.

About KORU Medical Systems

KORU Medical Systems, Inc develops and manufactures medical devices and supplies in the United States and internationally. It offers the freedom infusion systems to deliver life-saving therapies to patients with chronic illnesses, such as primary immunodeficiency diseases, chronic inflammatory demyelinating polyneuropathy, and paroxysmal nocturnal hemoglobinuria. Its products include the FREEDOM60 syringe infusion system, the FreedomEdge syringe driver, HIgH-Flo subcutaneous safety needle sets, and precision flow rate tubing products.